A clinical trial update on somatostatin receptor research was recorded on October 16, 2026. The study, registered as NCT06427798, is titled "Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy." The trial is listed as Phase 1/Phase 2 and its current status is recruiting.
This study targets patients with metastatic or inoperable SSTR-positive gastrointestinal neuroendocrine tumors, as well as pheochromocytoma and paraganglioma. Enrollment is limited to those previously treated with systemic targeted radioligand therapy. No results have been posted for this trial at this stage.
Somatostatin itself is classified as unapproved for research use and is not an approved therapeutic in this context. The trial listing does not provide efficacy or safety outcomes at this time, only the recruitment status and phase designation.
Readers interested in background on this compound can consult the somatostatin overview page for additional context.